Citius Oncology announces initial shipment of LYMPHIR to Europe

Citius Oncology (CTOR), a majority-owned subsidiary of Citius Pharmaceuticals, (CTXR), announced the initial shipment of LYMPHIR to Europe through one of its regional distribution partners, marking an important milestone in expanding access to the therapy for patients outside the United States. LYMPHIR will be made available to eligible patients through Named Patient Programs, or NPPs, in accordance with local regulations in each country. The initiation of European distribution represents a strategic step in the Company’s broader effort to extend access to LYMPHIR for patients with limited treatment options, while continuing to prioritize disciplined and targeted market entry. LYMPHIR was approved by the U.S. Food and Drug Administration in August 2024 for the treatment of adult patients with Stage I-III relapsed or refractory cutaneous T-cell lymphoma after at least one prior systemic therapy, and was commercially launched in the United States in December 2025. LYMPHIR does not have marketing authorization from the European Medicines Agency in Europe or other countries outside the U.S. Access is being provided solely through Named Patient Programs in accordance with applicable local laws and regulations.